Minimally Invasive Blood Lactate Biosensor

Information

  • Research Project
  • 6584962
  • ApplicationId
    6584962
  • Core Project Number
    R43HL072638
  • Full Project Number
    1R43HL072638-01
  • Serial Number
    72638
  • FOA Number
  • Sub Project Id
  • Project Start Date
    2/1/2003 - 22 years ago
  • Project End Date
    10/31/2003 - 21 years ago
  • Program Officer Name
    GOLDBERG, SUZANNE H.
  • Budget Start Date
    2/1/2003 - 22 years ago
  • Budget End Date
    10/31/2003 - 21 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -

Minimally Invasive Blood Lactate Biosensor

[unreadable] DESCRIPTION (provided by applicant): The overall aim of this research is to develop a micro-amperometric, minimally invasive, self-compensating, biosensor to continuously monitor blood lactate levels of patients during off pump coronary bypase surgery, and in CCU, ICU, emergency rooms, or post operative rooms, in point of care applications. One of the primary limitations in many current Continuous Monitoring System biosensors is their susceptibility to biofouling and encapsulation, which causes interference, drift and inaccuracies in reported results. The proposed lactate biosensor consists of a small diameter precious metal wire with a thin film of lactate oxidase immobilized on its surface, and a diffusion limiting, biocompatible membrane overcoat. This sensor will have a rapid and linear response over a wide dynamic range, be stable, readily replaced by an attending aide, and will have a low cost disposable sensor element integrated with reuseable sending and data logging units. Under Phase I the sensor configuration will be optimized and a linear response at concentrations up to 20 mM in buffer solution and serum, stability for at least 24 hours, sensor output repeatability, and the ability to inherently compensate for the effects of biofouling and encapsulation will be demonstrated. The major innovations present in this proposed development include the self-compensation feature; the use of a multi-layer membrane structure to reduce interference; and the use of biocompatible diffusion limiting coatings to minimize biofouling and sensor encapsulation. Preliminary testing conducted under internal funding has shown preliminary sensor feasibility in buffer solution. Once the sensor configuration has been optimized and met the Phase I demonstration criteria, more detailed Phase II testing are planned.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99454
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:99454\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MOHAWK INNOVATIVE TECHNOLOGY, INC.
  • Organization Department
  • Organization DUNS
    883926594
  • Organization City
    ALBANY
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    122052033
  • Organization District
    UNITED STATES